Clinical Research Directory

Inclusion Criteria: * The investigators concluded that the participants continued to benefit from treatment with Jaktinib. * The participants have been fully informed and voluntarily signed informed consent. * The participants completed the ZGJAK029 study for 16 weeks of treatment and visitation and had good compliance. * The interval between the participants' first dose and the last dose of ZGJAK029 ≤ 4 weeks. Exclusion Criteria: * There were any grade ≥3 adverse events within 4 weeks prior to enrollment and no return to grade 1 or normal. * Within 4 weeks prior to enrollment, participants had the following infectious diseases: tuberculosis infection requiring treatment; HIV-positive, syphilis, HBV infection, HCV infection. * The investigators considered participants unsuitable for this study.